Introduction
Despite many advances in antihypertensive treatment, blood pressure control remains far from perfect in clinical practice. 1, 2 The latest WHO/ISH guidelines 3 recommend initiating antihypertensive therapy either with monotherapy from six classes (± stepped care depending on response) or fixed lowdose combination therapy. The use of fixed lowdose combination therapy appears a novel strategy in the first-line management of mild to moderate hypertension 3, 4 but, in the light of the history of antihypertensive treatment, it is a logical development on the path to improved blood pressure control.
The early and modern periods in antihypertensive treatment
The history from the 1940s to the present can be roughly divided into an early period, comprising studies in severe hypertension up to 1970 and ending with the introduction of hydrochlorothiazide, and a modern period, namely the post-1970 studies in mild to moderate hypertension involving nondiuretic antihypertensive agents from beta-blockers to angiotensin II receptor antagonists. 5 The late 1940s and 1950s saw the introduction of medical therapy: early agents were effective in severe hypertension but had major side effects; in malignant hypertension, they significantly decreased mortality vs untreated patients and even vs surgery. 6 The use of chlorothiazide as an antihypertensive agent began in 1958 and decreased blood pressure significantly both in mono-and combination therapy. 7 The watershed between the early and modern periods was the publication in the August 1970 issue of JAMA 8 of the Veterans Administration study in the treatment of mild hypertension. It was the first prospective, randomised, double-blind study to show a significant decrease in morbidity and mortality by treating mild hypertension (diastolic: 90-114 mm Hg). This study, followed by others, led to the recommendation by the first Joint National Committee on Antihypertensive Treatment of a steppedcare approach: step 1-single drug therapy with a full dose of hydrochlorothiazide (50-100 mg daily); step 2-two-drug therapy with the addition of propanolol, methyldopa or reserpine; step 3-threedrug therapy with the addition of hydralazine or clonidine, ending with the addition of guanethidine. 9 This approach was supported by the Hypertension and Detection Follow-up Program (HDFP) study 10 which found a 17% decrease in mortality using a stepped-care versus referred-care approach.
The major monotherapy trials
With the arrival of new classes of antihypertensive treatment, it became important to determine which, if any, monotherapy was most effective in terms of blood pressure control and morbidity/mortality. A small decrease in mortality was observed with a beta-blocker vs chlorothiazide in the Metoprolol Atherosclerosis Prevention in Hypertensives (MAPHY) trial 11 but not in the Heart Attack Primary Prevention in Hypertension (HAPPHY) trial. 12 Neither the International Prospective Primary Prevention Study in Hypertension (IPPPSH) 13 nor the
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Medical Research Council Working Party study 14 showed any difference in efficacy between a betablocker and diuretic in terms of morbidity/mortality. However, in this last study, diuretics were found to be superior to beta-blockers in the subgroup of elderly patients. The Treatment of Mild Hypertension Study (THOMS) 15 of five different treatments (acebutolol, amlodipine, enalapril, chlorthalidone, doxazosin) vs placebo found only minor and inconsistent differences between treatments, including blood pressure reduction, and substantial blood pressure reduction on placebo. A Veterans Affairs study 16, 17 of six antihypertensive treatments, including captopril, atenolol and diltiazem, found no significant differences between monotherapies; however, there was clear individual variability in blood pressure response to the treatments, suggesting potential benefit from sequential monotherapy. 17 The recent Swedish Trial in Old Patients with Hypertension-2 study 18 showed that old and new antihypertensive drugs were similar in prevention of cardiovascular mortality or major events but the frequenties of myocardial infarctions and of congestive heart failure were significantly lower in patients treated with ACE inhibitors than in those receiving calcium antagonists in this trial.
Experiments in combination therapy
The stepped-care approach prompted attempts at combination therapy, eg the IPPPSH study, 13 where 67% of patients randomised to the beta-blocker group received a diuretic and 33% a third drug, achieving blood pressure control in 80% overall. However, failure of monotherapy to control blood pressure in a substantial proportion of patients-25 to 67% 13-17 -using either stepped-care or sequential strategy led to trials of second-line therapy with a full-dose two-drug combination. For example, captopril 75 mg + hydrochlorothiazide 45 mg daily was superior to either drug alone in blood pressure control but had more dose-dependent side effects. 19 Two-drug therapy comprising a diuretic has proved particularly effective in controlling systolic blood pressure. 20 Long-term control is a major concern in antihypertensive therapy. In the Behandla Blodtryck Bättre/Treat Blood Pressure Better (BBB) trial, 21 after 4 years, the group with a target diastolic blood pressure below 80 mm Hg required a mean of 2.0 antihypertensive drugs compared to 1.6 drugs in the controls, vs a common baseline of 1.2 drugs, with no change in blood pressure control. In the Hypertension Optimal Treatment (HOT) study, 22, 23 62-76% of patients required more than one antihypertensive drug at 36 months' follow-up, while at 9 years' follow-up in the United Kingdom Prospective Diabetes Study (UKPDS) 38 trial, 24 60% of patients required two-or three-drug therapy in the 'tight blood pressure control' group vs 40% in the 'less tight blood pressure control' group. Thus it seems that long-term blood pressure control is unattainable in many patients without a minimum of two-drug therapy. This provides the rationale for combination therapy. However, due to side effects of both components in such combination, 25 they are recommended in second-intention.
French and British epidemiological data suggest that clinically we are probably still in the prehistory of hypertension management: in France, only 60% of hypertensive patients are treated, and blood pressure control is optimal in only 14%; 2 the respective UK data are 26 and 6%. 1 However, it may be noted that the definition of optimal blood pressure control of less than 140/90 mm Hg used to calculate these percentages is more restrictive than the definition used clinically at the time of these studies (Ͻ160/90 mm Hg). On the other hand, the side effects of antihypertensive drugs are a problem at not only the individual but also the social level; they may contribute to the 20-40% excess absenteeism in treated hypertensive patients vs the general population. 26 These data are crucial in showing how far we still have to go on the ground as opposed to the rarefied world of randomised studies. How therefore are we to improve blood pressure control while limiting side effects? New monotherapies are probably not the complete answer: a recent study showed that full-dose monotherapy with an angiotensin II receptor antagonist controls only 50% of patients, though with few side effects. 5
Fixed low-dose combination therapy in first-line management
The idea of first-line therapy with a fixed low-dose combination was the obvious response to studies showing the limitations of single-drug strategies. The rationale is evidence-based (Table 1) . 25, 27, 28 Low-dose two-drug therapy controls blood pressure in over three patients in four without significant side effects. 27 However, it remains to be demonstrated that fixed low-dose combination in the first instance will reduce mortality compared to a stepped-care approach by large clinical trials.
Three fixed low-dose antihypertensive therapies have been approved for first-line use by regulation authorities: two in the US, bisoprolol-hydrochloro- Increased target organ protection (potential advantage unproven at that time) thiazide and captopril-hydrochlorothiazide, and two in France, perindopril-indapamide and bisoprololhydrochlorothiazide. The perindopril-indapamide and bisoprolol-hydrochlorothiazide combinations have been evaluated in recent clinical trials for firstline use.
In France, the first approved combination was perindopril 2 mg + indapamide 0.625 mg. 29, 30 Administered alone at these doses, neither component has antihypertensive effect vs placebo. In combination, however, their short-term antihypertensive effect at least equals that of conventional full-dose monotherapies. 31 Thus the activity of this low-dose combination is clearly due to the additive effects of the components, while side effects are reduced.
In a recent randomised double-blind study, 32 383 elderly hypertensives (Ͼ65 years) received perindopril 2 mg + indapamide 0.625 mg or placebo daily. Blood pressure was determined monthly (target diastolic blood pressure: Ͻ90 mm Hg) and side effects at 3 and 12 months: 80% of treated patients remained normalised throughout follow-up. The mean reductions in systolic/diastolic blood pressure were 23/13 mm Hg vs 12.3/7.3 mm Hg on placebo; side effect rates did not differ (18.8% vs 19.7%, respectively). In the isolated systolic hypertension subgroup (n = 123, systolic hypertension defined as systolic blood pressure superior to 160 mm Hg and diastolic inferior to 95 mm Hg), the decrease in systolic blood pressure over 3 months was 9.8 mm Hg greater than on placebo; systolic blood pressure remained normalised (Ͻ160 mm Hg) in over 80% of patients in the 48 weeks of the extension study. 33 Since these are better long-term control results than with any first-line monotherapy, 16, 21, 22 this combination appears a valid alternative to the conventional stepped-care or sequential approaches used to initiate antihypertensive treatment. For example, in the SHEP trial, 34 the decrease in systolic blood pressure under treatment was 11 mm Hg greater than on placebo but these results were obtained with chlorthalidone alone in only 55% of patients.
The second approved combination for first-line use originated in the US, 25, 27, 35, 36 fixed bisoprolol + hydrochlorothiazide therapy was approved by the FDA in 1997, and in France this year. The hydrochlorothiazide diuretic is administered at a fixed dose of 6.25 mg and bisoprolol at varying doses (2.5, 5, and 10 mg). The combination is effective vs placebo in terms of blood pressure reduction and percentage of patients controlled, and has few side effects; vs conventional monotherapy, it is equal or even superior in terms of blood pressure control, with a trend towards fewer side effects. 34, 35 Compared to amlodipine 5 mg in the French Ultra Low Dose in Systolic Hypertension Study 37 in 164 elderly patients with isolated systolic hypertension, it was similar in the rates of response (systolic: р160 mm Hg or decrease у10%), normalisation (systolic: р140 mm Hg), and overall adverse events over 12 weeks: 54 vs 56%, 31 vs 23%, and Journal of Human Hypertension 36 vs 40%, respectively. However, studies are limited by the short follow-up (12 weeks): the efficacy/tolerability ratio needs stringent evaluation over at least 12 months.
Conclusion
Further studies are needed to ensure that these combinations not only control blood pressure but also have positive target organ effects, decrease morbidity and mortality, and increase compliance. However, according to the latest international guidelines, they can already be considered effective and safe in the first-line therapy of essential hypertension and isolated systolic hypertension in adults and the elderly. Fixed low-dose combination therapy may have the potential to improve hypertension control in the overall population and prevent the associated cardiovascular complications.
